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Abstract: Oral rotavirus vaccines have consistently proven to be less 
immunogenic among infants in developing countries. Discrepancies in the 
intestinal microbiota, including a greater burden of enteropathogens and 
an altered commensal community composition, may contribute to this trend 
by inhibiting the replication of vaccine viruses. To test this 
possibility, we performed a nested case-control study in Vellore, India, 
in which we compared the intestinal microbiota of infants who responded 
serologically or not after two doses of Rotarix delivered at 6 and 10 
weeks of age as part of a clinical trial (CTRI/2012/05/002677). The 
prevalence of 40 bacterial, viral, and eukaryotic pathogen targets was 
assessed in pre-vaccination stool samples from 325 infants using 
singleplex real-time PCR on a Taqman array card (TAC). In a subset of 170 
infants, we assessed bacterial microbiota composition by sequencing the 
16S rRNA gene V4 region. Contrary to expectations, responders were more 
likely than non-responders to harbor ≥1 bacterial enteropathogen at dose 
1 (26% [40/156] vs 13% [21/157] of infants with TAC results who completed 
the study per protocol; χ2, P = 0.006), although this was not apparent at 
dose 2 (24% [38/158] vs 23% [36/158]; P = 0.790). Rotavirus shedding 
after dose 1 was negatively correlated with the replication of co-
administered oral poliovirus vaccine (OPV). We observed no consistent 
differences in composition or diversity of the 16S bacterial microbiota 
according to serological response, although rotavirus shedding was 
associated with slightly more bacterial taxa pre-vaccination. Overall, 
our findings demonstrate an inhibitory effect of co-administered OPV on 
the first dose of Rotarix, consistent with previous studies, but in the 
context of OPV co-administration we did not find a strong association 
between other components of the intestinal microbiota at the time of 
vaccination and Rotarix immunogenicity. 
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Abstract 23 
Oral rotavirus vaccines have consistently proven to be less immunogenic among infants in developing 24 
countries. Discrepancies in the intestinal microbiota, including a greater burden of enteropathogens and 25 
an altered commensal community composition, may contribute to this trend by inhibiting the replication 26 
of vaccine viruses. To test this possibility, we performed a nested case–control study in Vellore, India, in 27 
which we compared the intestinal microbiota of infants who responded serologically or not after two 28 
doses of Rotarix delivered at 6 and 10 weeks of age as part of a clinical trial (CTRI/2012/05/002677). 29 
The prevalence of 40 bacterial, viral, and eukaryotic pathogen targets was assessed in pre-vaccination 30 
stool samples from 325 infants using singleplex real-time PCR on a Taqman array card (TAC). In a 31 
subset of 170 infants, we assessed bacterial microbiota composition by sequencing the 16S rRNA gene 32 
V4 region. Contrary to expectations, responders were more likely than non-responders to harbor ≥1 33 
bacterial enteropathogen at dose 1 (26% [40/156] vs 13% [21/157] of infants with TAC results who 34 
completed the study per protocol; χ2, P = 0.006), although this was not apparent at dose 2 (24% [38/158] 35 
vs 23% [36/158]; P = 0.790). Rotavirus shedding after dose 1 was negatively correlated with the 36 
replication of co-administered oral poliovirus vaccine (OPV). We observed no consistent differences in 37 
composition or diversity of the 16S bacterial microbiota according to serological response, although 38 
rotavirus shedding was associated with slightly more bacterial taxa pre-vaccination. Overall, our findings 39 
demonstrate an inhibitory effect of co-administered OPV on the first dose of Rotarix, consistent with 40 
previous studies, but in the context of OPV co-administration we did not find a strong association 41 
between other components of the intestinal microbiota at the time of vaccination and Rotarix 42 
immunogenicity.  43 
  44 
 3 
1. Introduction 45 
Each year, an estimated 215,000 children die of severe gastroenteritis associated with rotavirus 46 
infection, including between 47,000 and 79,000 in India [1, 2]. Although two internationally-licensed oral 47 
rotavirus vaccines, Rotarix (RV1) and RotaTeq, are currently available, their efficacy is impaired in low-48 
income countries [3]. Mechanisms responsible for this phenomenon remain uncertain, but may include 49 
maternal antibodies, histo blood group antigen phenotype, malnutrition, environmental enteropathy, and 50 
enteric infections [4-7]. In a systematic review of oral poliovirus vaccine (OPV) trials, we observed a 51 
reduction in the odds of seroconversion and vaccine virus shedding among individuals infected with non-52 
polio enteroviruses (NPEVs) [8]. Similarly, during a recent study in Bangladesh, enterovirus quantity at 53 
the time of immunization was negatively correlated with the immunogenicity of both OPV and RV1 [9].  54 
The composition of the bacterial microbiota may also shape response to oral vaccines. Viruses exploit 55 
microbiota-derived compounds to replicate efficiently in the intestinal mucosa, as evidenced by the 56 
reduced pathogenicity of poliovirus and rotavirus in antibiotic-treated mice [10, 11]. Significant 57 
geographic variation occurs in the composition of the infant microbiota [12, 13], which may in turn 58 
contribute to discrepancies in vaccine performance. 59 
We carried out a nested case–control study among infants enrolled in a clinical trial of RV1 60 
immunogenicity in India (Lazarus et al). Herein, we tested the hypothesis that failure to seroconvert 61 
would be associated with an elevated pathogen burden and an altered bacterial microbiota composition. 62 
 63 
2. Materials and Methods 64 
2.1. Study population 65 
Full details of the study design, laboratory procedures, and statistical analyses are provided in the 66 
Supplementary Methods. Samples were obtained from a randomized, placebo-controlled trial assessing 67 
the impact of daily supplements of zinc and/or probiotics (Lactobacillus rhamnosus GG) on the 68 
immunogenicity of RV1 and OPV doses co-administered at 6 and 10 weeks of age (Lazarus et al, co-69 
submitted). The trial was performed in Chinnallapuram, a densely populated urban area in Vellore, India 70 
[14]. Infants were considered eligible for enrollment if they were between 35 and 41 days of age, weighed 71 
at least 3.2 kg, were available for the duration of the follow-up period, and had no medical conditions that 72 
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precluded involvement. Written informed consent was obtained from parents or guardians prior to 73 
recruitment. Infants received routine vaccines according to the national schedule in India, including OPV 74 
at birth, but were excluded if they had received any other doses of OPV or rotavirus vaccine.  75 
Serum anti-rotavirus VP6 IgA antibodies were measured at 6 and 14 weeks of age using an antibody-76 
sandwich enzyme immunoassay [15]. Rotavirus seroconversion was defined as a four-fold increase in 77 
anti-VP6 IgA concentration or detection of antibodies at ≥20 U/ml in previously seronegative infants. 78 
Hereafter, we refer to infants who seroconverted to rotavirus as responders and infants who failed to 79 
seroconvert as non-responders.  80 
Following completion of the trial, we conducted a nested case–control study to assess the association 81 
between enteropathogens and RV1 response. Infants were considered eligible for the study if they 82 
received supplements or placebo, received scheduled doses of OPV and RV1, and provided paired serum 83 
samples. To meet sample size requirements (Supplementary Methods), we analyzed stool samples from 84 
all responders, subject to constraints in sample availability (n = 162). We randomly selected an 85 
approximately equal number of non-responders from each study arm (n = 163) to account for the potential 86 
confounding of treatment group with enteropathogen burden. Baseline characteristics were comparable 87 
between responders and non-responders (Table 1). 88 
In a subset of 170 infants that had been assessed for enteropathogen burden (including 85 responders), 89 
we sequenced the 16S rRNA gene V4 region in stool samples collected before each RV1 dose to assess 90 
the intestinal bacterial microbiota. For this microbiota subset we preferentially sampled recipients of 91 
placebo-only and probiotics-only, enabling us to assess the effect of probiotics on microbiota composition 92 
as a secondary objective.  93 
 94 
2.2. Enteropathogen testing by TaqMan array card 95 
Stool samples were obtained on the day of or preceding each vaccine dose. These were kept at room 96 
temperature until collection (which typically occurred within 4 hours), transported in cold boxes to the 97 
laboratory, then stored at -70°C until testing, with up to two intervening freeze–thaw cycles for 98 
aliquoting. We extracted DNA and RNA from 200 mg of the 6- and 10-week pre-vaccination stools from 99 
each infant and assessed the presence of 40 enteropathogen targets via real-time reverse transcription PCR 100 
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(RT-PCR) using TaqMan array cards (TACs) [16, 17]. A threshold cycle (Ct) value of 35 was used as a 101 
cut-off for pathogen detection [16]. Enterovirus-positive samples were assessed for the presence of Sabin 102 
polioviruses using multiplex RT-PCR [18]. To assess RV1 replication (or ‘take’), we quantified rotavirus 103 
shedding in samples collected pre-vaccination (indicative of natural rotavirus exposure) and 4 and 7 days 104 
after the 6-week dose using a VP6-specific real-time RT-PCR assay [19, 20]. 105 
 106 
2.3. Characterization of the intestinal microbiota by 16S rRNA gene sequencing 107 
Our laboratory and bioinformatic pipeline for assessment of the bacterial microbiota have previously 108 
been described [21]. We amplified the 16S rRNA gene V4 region using primers 515F (5’-109 
GTGCCAGCAGCCGC-GGTAA-3’) and 806R (5’-GGACTACCAGGGTAT-CTAAT-3’) in DNA 110 
extracted from stool samples collected at 6 and 10 weeks of age in each infant. Purified PCR products 111 
were sequenced in two Illumina MiSeq runs (2 x 151 bp) [22]. Reads were assembled using FLASH [23] 112 
and analyzed using macQIIME (version 1.8.0) [24]. After quality filtering [25] and chimera removal, 113 
sequences were clustered de novo into operational taxonomic units (OTUs) with ≥97% nucleotide identity 114 
using uclust and taxonomically assigned using the RDP classifier [26].  115 
 116 
2.4. Statistical analysis 117 
2.4.1. Enteropathogen burden 118 
Analyses were performed on infants who completed the study per protocol (as defined by Lazarus et 119 
al). Our primary outcome was the association between rotavirus seroconversion and the presence of ≥1 120 
enteropathogen at 6 or 10 weeks of age, as determined via logistic regression. We excluded 121 
enteroaggregative Escherichia coli (EAEC) from the primary outcome analysis based on the high 122 
prevalence of this target in an interim analysis and its limited association with diarrhea during previous 123 
studies in resource-poor settings using TACs [27], and enteroviruses given that they may reflect 124 
replication of OPV rather than natural enteropathogen exposure.  125 
As secondary outcomes, we compared the prevalence of individual pathogens, pathogen groups 126 
(bacterial, viral, eukaryotic, or any), mixed infections (defined as >1 enteropathogen), Sabin viruses, and 127 
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concurrent diarrhea (defined as ≥3 loose stools in a 24-hour period within the 7 days preceding 128 
vaccination) according to RV1 outcome (seroconversion/shedding) at each dose using the χ2 test or 129 
Fisher’s exact test (the latter applied if there were <5 infected or uninfected individuals in a given 130 
comparison). The presence of an enterovirus in the absence of any Sabin viruses was defined as an 131 
NPEV, though notably our assays did not allow distinction of samples positive for both Sabin viruses and 132 
NPEVs. For prevalence estimates, 95% confidence intervals (CIs) were calculated using the Clopper–133 
Pearson exact method [28]. Wilcoxon’s rank sum test was used to compare total pathogen count and Ct 134 
values at each dose according to RV1 outcome; lower Ct values correspond to higher target copy numbers 135 
and were used as an indicator of increased pathogen abundance. Rotaviruses were excluded from analyses 136 
of mixed infections, pathogen groups, and pathogen count given that, in contrast to the hypothesized 137 
inhibitory effect of enteropathogens, one would expect natural rotavirus exposure or RV1 shedding to be 138 
positively correlated with rotavirus seroconversion. Across the 6- and 10-week doses, we assessed the the 139 
association between the number of doses in which ≥1 enteropathogen was present (0, 1, or 2) and 140 
rotavirus seroconversion via logistic regression.  141 
Type 3 poliovirus seroconversion rate was compared according to rotavirus seroconversion using the 142 
χ2 test, as was the prevalence of dose 1 rotavirus shedding. To assess the potential impact of poliovirus 143 
replication following the birth dose of OPV on the take of OPV administered at 6 weeks, we compared 144 
the shedding of enteroviruses (including Sabin serotypes and NPEVs) at 10 weeks of age (i.e., 4 weeks 145 
after vaccination) according to whether ≥1 Sabin serotype was present in the 6-week samples (also using 146 
the χ2 test).  147 
P values of 0.05 were considered significant. For comparisons of prevalence or abundance for 148 
individual TAC targets present in at least 1% of the study population, P values were adjusted via 149 
Benjamini–Hochberg false discovery rate (FDR) correction [29]. All analyses were carried out in the 150 
programming language R [30]. 151 
 152 
2.4.2. Microbiota composition 153 
After quality filtering, we obtained a minimum of 3,726 sequences per sample, which we standardized 154 
to 3,500 sequences per sample. For comparisons of within-sample (alpha) diversity, we evaluated OTU 155 
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count (overall and within the enteropathogen-rich phylum Proteobacteria) and Shannon index as 156 
continuous dependent variables via linear regression. Unweighted and weighted Unifrac distances were 157 
used to assess divergence between samples (beta diversity), and cluster significance determined using the 158 
adonis function in the R package vegan [31]. We also used Unifrac distances between samples collected 159 
from the same infant over time as a measure of microbiota stability, and compared this measure between 160 
infants using Wilcoxon’s rank sum test. Differences in relative taxon abundance were assessed using a 161 
non-parametric test based on a bootstrapped t statistic [32]. We report on any associations with a P value 162 
of <0.15 after FDR correction. Random Forest models were fit to discriminate infants according to RV1 163 
outcome and study arm based on OTU abundances [33]. 164 
 165 
2.4.3. Sensitivity analyses 166 
We carried out sensitivity analyses to assess the influence of Ct threshold, study arm, amplification 167 
efficiency of MS2 (the extrinsic RNA control in the TACs), baseline rotavirus-specific IgA status, and 168 
seroconversion criteria on the comparisons described above. 169 
 170 
3. Results 171 
3.1. RV1 immunogenicity 172 
A companion paper describes the primary outcomes of the trial (Lazarus et al). Briefly, out of 551 173 
individuals who completed the study per protocol, 173 (31%) seroconverted to rotavirus, including 174 
54/137 (39%) recipients of zinc and probiotics, 42/136 (31%) probiotics recipients, 40/143 (28%) zinc 175 
recipients, and 37/135 (27%) placebo recipients. Infants receiving probiotics (arms 1+2) or zinc 176 
supplementation (arms 1+3) did not differ significantly in their rate of seroconversion compared with 177 
placebo recipients (arms 3+4 or 2+4, respectively). However, a significant increase in seroconversion rate 178 
was observed among infants who received both supplements compared with those who received neither 179 
(Fisher’s exact test, P = 0.040).  180 
 181 
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3.2. Association between pathogen burden and seroconversion 182 
i. Primary outcome  183 
We assessed the presence of enteropathogens using TACs in 325 infants (Table 1). Among per-184 
protocol infants (n = 320), we obtained eligible TAC assays (positive for the extrinsic DNA control and at 185 
least one RNA target) for 6-week samples in 313 infants, 10-week samples in 316 infants, and 6- and 10-186 
week samples in 309 infants. We observed ≥1 enteropathogen (excluding EAEC, enterovirus, and 187 
rotavirus) at either 6 or 10 weeks in 70/154 (45%) non-responders and 78/155 (50%) responders (odds 188 
ratio [OR] 1.22, 95% CI 0.78–1.90). 189 
ii. Secondary outcomes 190 
EAEC and enteroviruses were the predominant TAC targets at 6 and 10 weeks (Figures 1A and 1B). 191 
Their prevalence did not differ significantly according to seroconversion status (Supplementary Table 1), 192 
although enterovirus abundance was greater among responders than non-responders at 6 weeks (Ct, 29.5 193 
± 4.5 [mean ± standard deviation (SD)] vs 31.0 ± 4.1; Wilcoxon’s rank sum, FDR-corrected P = 0.042). 194 
The majority of enterovirus-positive samples (155/217 [71%] and 176/235 [75%] at 6 and 10 weeks, 195 
respectively) contained ≥1 Sabin serotype (Supplementary Figure 1).  196 
Other enteropathogens were generally more common in RV1 responders than non-responders at 6 197 
weeks (Figure 1A), although no individual comparisons of prevalence or abundance were significant after 198 
FDR adjustment (Supplementary Table 1). Combining across TAC targets, ≥1 enteropathogen (excluding 199 
EAEC, enterovirus, and rotavirus) was observed in 56/156 (36%) responders and 37/157 (24%) non-200 
responders at 6 weeks (χ2, P = 0.017). This discrepancy can be attributed primarily to bacterial pathogens, 201 
which were more common in RV1 responders than non-responders (40/156 [26%] vs 21/157 [13%] 202 
excluding EAEC; χ2, P = 0.006). These differences were no longer apparent at 10 weeks (Figure 1B). The 203 
prevalence of viral enteropathogens other than enteroviruses and of eukaryotic enteropathogens did not 204 
differ significantly between responders and non-responders at either dose. 205 
We detected up to six pathogens per sample with an average of 1.6 (SD 1.0) and 1.8 (SD 1.0) at 6 and 206 
10 weeks, respectively. The prevalence of mixed infections did not differ significantly according to 207 
seroconversion status at 6 or 10 weeks (χ2, P values >0.05), nor did total pathogen count (Wilcoxon’s 208 
rank sum, P values >0.05; Figures 1C and 1D). Concurrent diarrhea was documented in <5% of 209 
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individuals at 6 and 10 weeks; this proportion did not differ between responders and non-responders at 210 
either dose (χ2, P values >0.05). 211 
 212 
3.1.3. Pathogen prevalence over successive doses  213 
Compared with infants clear of enteropathogens at both 6 and 10 weeks, we observed a significant 214 
increase in the odds of seroconversion when ≥1 pathogen (excluding EAEC, enterovirus, and rotavirus) 215 
was present at both doses (OR 2.25, 95% CI 1.15–4.41; Figure 1E) – an effect that was absent among 216 
individuals infected at only one dose (OR 0.91, 95% CI 0.55–1.50). A similar trend was apparent when 217 
considering only bacterial pathogens (OR 1.32, 95% CI 0.76–2.31 and OR 1.98, 95% CI 0.93–4.23 in 218 
association with the presence of ≥1 bacterial pathogen [excluding EAEC] at one or both doses, 219 
respectively). 220 
 221 
3.2. Association between enteropathogen burden and RV1 take 222 
Rotavirus shedding at >100 copies per reaction at 4 and/or 7 days following the first dose of RV1 was 223 
observed in 66/278 (24%) per-protocol infants with complete samples and no pre-vaccination shedding 224 
(Supplementary Figure 2). Among shedders, 46/66 (70%) seroconverted, compared with 95/212 (45%) 225 
non-shedders (χ2, P <0.001). Baseline characteristics were comparable between shedders and non-226 
shedders (Supplementary Table 2), with the exception of rotavirus-specific serum IgA, which was 227 
detected in 8/66 (12%) shedders and 65/212 (31%) non-shedders (Fisher’s exact test, P = 0.002). We 228 
observed no association between intestinal bacteria, eukaryotes, mixed infections, concurrent diarrhea, or 229 
pathogen count at 6 weeks and the prevalence of shedding (P values >0.05; Figure 2A; Supplementary 230 
Table 3). Enterovirus abundance at 6 weeks was significantly greater in shedders than non-shedders (Ct, 231 
28.8 ± 4.3 vs 30.5 ± 4.3; Wilcoxon’s rank sum, FDR-corrected P = 0.046; Supplementary Table 3) – a 232 
discrepancy attributable in part to a greater prevalence of Sabin viruses (Figure 2B). In addition, shedding 233 
of rotavirus appears to be associated with the diminished replication of co-administered OPV, since 234 
enterovirus prevalence at 10 weeks of age (i.e., 4 weeks later) was lower in rotavirus shedders than non-235 
shedders (39/65 [60%] vs 166/210 [79%]; χ2, P = 0.014; Figure 2C) – a trend that was also evident among 236 
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Sabin viruses (29/64 [45%] vs 122/209 [58%]; χ2, P = 0.066). Nonetheless, after two doses rotavirus 237 
seroconversion did not differ by type 3 poliovirus seroconversion status (146/447 [33%] seroconverted 238 
among poliovirus sero-responders and 26/103 [25%] among non-responders; χ2, P = 0.143). Poliovirus 239 
shedding at 10 weeks was significantly lower among individuals shedding poliovirus at 6 weeks (Figure 240 
2D). 241 
 242 
3.3. Association between bacterial microbiota composition and RV1 outcome 243 
We obtained an average of 25,254 (SD 13,091) sequences per sample, encompassing 153 OTUs. The 244 
composition of the microbiota was similar at 6 and 10 weeks (Figure 3A), with a small number of 245 
dominant OTUs (Supplementary Figure 3).  246 
Analyses of alpha and beta diversity are summarized in Supplementary Table 4. We observed no 247 
significant differences in microbiota diversity (Figure 3B), stability (Supplementary Figure 4), or taxon 248 
relative abundance (non-parametric t test, FDR-corrected P values >0.15; Supplementary Table 5) 249 
according to seroconversion status, and no significant clustering of samples based on Unifrac distances 250 
(adonis, P values >0.05; Figure 3C; Supplementary Figure 5). Infants who shed rotavirus 4 and/or 7 days 251 
after the 6-week RV1 dose harbored a greater number of OTUs before vaccination (linear regression, P = 252 
0.007; Figure 3D). We also observed a significant difference in pre-vaccination microbiota composition 253 
according to shedding status based on unweighted Unifrac (adonis, P = 0.032; Figure 3E), but this 254 
accounted for a very small portion of the variance among samples (R2 = 0.012). Rotavirus shedding was 255 
not associated with microbiota stability between 6 and 10 weeks (Supplementary Figure 4C), nor did we 256 
observe any differences in pre-vaccination taxon abundance between shedders and non-shedders (non-257 
parametric t test, FDR-corrected P values >0.15). At 10 weeks, a modest enrichment of the phyla 258 
Bacteroidetes and Verrucomicrobia was observed among infants who shed rotavirus following the 6-week 259 
RV1 dose (Supplementary Table 6). 260 
Random Forest models based on OTU abundance data failed to accurately predict rotavirus 261 
seroconversion (mean accuracy 43.4% and 45.7% at 6 and 10 weeks, respectively; baseline accuracy, 262 
50.6%; P values >0.05), but showed modest predictive accuracy for shedding after dose 1 (mean accuracy 263 
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60.3% and 60.8% based on OTUs measured at 6 and 10 weeks, respectively; baseline accuracy, 50.0%; P 264 
= 0.038 and 0.040; Supplementary Figure 6). 265 
 266 
3.4. Impact of probiotics on the bacterial microbiota 267 
Our study was designed to compare microbiota composition according to seroconversion status, and 268 
we therefore included an equal number of responders and non-responders rather than a random sample 269 
from each study arm. However, since 16S microbiota composition was not strongly correlated with 270 
seroconversion status, we pursued an exploratory analysis of microbiota diversity and composition by 271 
study arm. Overall, the impact of study arm was modest (Figure 4), as discussed further in the 272 
Supplementary Results. The probiotic strain appears to correspond to a single OTU, classified as 273 
Lactobacillus zeae, which was more prevalent and abundant in infants receiving the probiotic intervention 274 
(Figure 4A). Among probiotic recipients, pre-vaccination abundance of this OTU was associated with 275 
rotavirus  shedding after dose 1, but not seroconversion (Supplementary Figure 7). 276 
 277 
3.5. Sensitivity analyses 278 
Sensitivity analyses are discussed in the Supplementary Results. 279 
 280 
Discussion 281 
Throughout early life, infants living in resource-poor settings are exposed to multiple, diverse 282 
enteropathogens. The negative repercussions of repeated pathogen exposure include deficits in growth 283 
[34], gut integrity [35], and OPV immunogenicity [8]. Among infants in south India, we observed a high 284 
prevalence of enteropathogens (albeit generally in the absence of symptoms). However, we did not 285 
observe an inhibitory effect of these enteropathogens on RV1. Indeed, infants harboring ≥1 bacterial 286 
pathogen during both doses were more likely to respond to this vaccine.  287 
Rotavirus shedding following the 6-week vaccine dose was positively associated with rotavirus 288 
seroconversion but negatively correlated with the take of co-administered OPV. This observation is 289 
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consistent with an inhibitory effect of OPV on RV1 (although we observed no association between the 290 
immunogenicity of these vaccines after two doses) [36]. Given their potential to interfere with OPV [8], 291 
the presence of pathogenic bacteria at 6 weeks of age may perhaps have enhanced RV1 immunogenicity 292 
by inhibiting the replication of co-administered Sabin viruses. Alternatively, concurrent bacteria may 293 
have promoted RV1 immunogenicity via an adjuvant effect (e.g., through the induction of TLR 294 
signaling). It is worth noting, however, that the association between bacterial pathogens and RV1 295 
response was contingent on the exclusion of EAEC, which we omitted from primary comparisons because 296 
of its high prevalence and limited association with diarrhea during previous studies in resource-poor 297 
settings using TACs [27]. Irrespective of whether EAEC was included, our findings do not support the 298 
view that bacterial pathogens impair the immunogenicity of RV1 – a conclusion consistent with recent 299 
findings from Bangladesh [9]. 300 
Infants who shed rotavirus after their 6-week RV1 dose exhibited a higher prevalence of enteroviruses 301 
at the time of vaccination. These enteroviruses can be attributed primarily to the residual replication of 302 
Sabin viruses administered at birth. Again, this observation may relate to the replication of Sabin viruses 303 
co-administered with RV1. The take of OPV given at 6 weeks was diminished among infants shedding 304 
Sabin viruses at that time, potentially reflecting an inhibitory effect of continued replication of the OPV 305 
birth dose or of vaccine-induced mucosal immunity. By either mechanism, existing Sabin polioviruses 306 
may have enhanced RV1 response by inhibiting the replication of co-administered OPV (conceptual 307 
model in Supplementary Figure 8). Prior rotavirus exposure, inferred by the presence of rotavirus-specific 308 
serum IgA at baseline, has been linked with impaired RV1 immunogenicity in several previous studies [6, 309 
37]. Here, IgA seropositivity at baseline was negatively correlated with dose 1 shedding but not with 310 
seroconversion after two doses. 311 
We observed no differences in the composition or stability of the bacterial microbiota according to 312 
rotavirus seroconversion status. A greater OTU count and shift in overall community structure was 313 
apparent in individuals who shed rotavirus after the first RV1 dose. However, the size of this effect was 314 
modest and was not indicative of dysbiosis. These findings do not necessarily preclude a role of the 315 
intestinal microbiota in shaping broader geographic trends in RV1 immunogenicity. The composition of 316 
the microbiota among infants in this study is likely to differ considerably from that of infants in high-317 
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income countries [12]. Given the poor seroconversion rates observed in this trial (31%), it is possible that 318 
all infants harbored a bacterial community structure inhibitory to RV1 replication. 319 
Our findings are at odds with a recent study of RV1 in Ghana, wherein infants who seroconverted 320 
exhibited a lower abundance of Bacteroidetes, a higher abundance of bacteria related to Streptococcus 321 
bovis, and a microbiota composition closer to that of Dutch infants compared with non-seroconverters 322 
[38]. The authors of that paper speculate that bacteria related to S. bovis may be more immunostimulatory 323 
than those in the Bacteroidetes phylum, potentially acting as an adjuvant to the rotavirus vaccine. 324 
However, we observed no significant differences in microbiota composition (including Streptococcus 325 
abundance) according to RV1 seroconversion and greater abundance of Bacteroidetes at 10 weeks of age 326 
among rotavirus shedders. These discrepancies may reflect differences in methodology (next-generation 327 
sequencing versus microarray) or baseline microbiota composition, and highlight the difficulties that are 328 
likely to be faced in identifying mechanistic links between the intestinal microbiota and oral vaccine 329 
outcome using observational data. 330 
The administration of probiotics had a minimal impact on the intestinal microbiota of these infants, as 331 
illustrated by the failure of Random Forest models to accurately distinguish infants by study arm when 332 
the OTU corresponding to the probiotic strain was omitted. Despite the daily administration of 1010 333 
organisms, the enriched OTU accounted for a mean relative abundance of <1% among probiotic 334 
recipients at 6 and 10 weeks, potentially reflecting passive transit rather than successful colonization.  335 
Our study was limited by the lack of shedding data for the second RV1 dose. Although demography, 336 
growth, and several other baseline characteristics did not differ between the responders and non-337 
responders included in this study, we did not consider several other potential confounders that may 338 
influence microbiota composition in early infancy, such as mode of delivery and antibiotic exposure [21, 339 
39]. Factors such as primer selection and sample handling (e.g., freeze–thaw cycles) may have introduced   340 
bias into our assessment of microbiota composition [40, 41]. However, these were present across all 341 
samples and would therefore have influenced comparison groups equally. Finally, co-administration of 342 
OPV may have obscured a role for other enteric viruses, particularly NPEVs, in shaping RV1 343 
immunogenicity. Further study among infants receiving inactivated rather than oral poliovirus vaccine 344 
would allow the significance of NPEVs for RV1 immunogenicity to be tested. 345 
 14 
Overall, our findings support a modest inhibitory effect of co-administered OPV on the first dose of 346 
RV1. However, we did not observe a greater pathogen burden among infants who failed to respond to 347 
RV1, nor did we observe any major differences in bacterial microbiota composition in these individuals. 348 
Future studies on a broader geographic and socioeconomic scale, or those considering different aspects of 349 
microbial community composition or function, may yet reveal an important role for the intestinal 350 
microbiota in shaping RV1 response. 351 
 352 
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Figure legends 470 
Figure 1. Association between concurrent pathogens and seroconversion after two doses of Rotarix. 471 
Prevalence of concurrent pathogens at (A) 6 weeks and (B) 10 weeks of age by seroconversion status. 472 
Pathogens present in at least 1% of the study population are included. (C, D) Pathogen count and mixed 473 
infection prevalence at (C) 6 weeks and (D) 10 weeks of age by seroconversion status. Mean pathogen 474 
counts are indicated by dotted lines. (E) Impact of concurrent enteropathogens at 6 and 10 weeks of age 475 
on the odds of seroconversion. Rotaviruses were excluded from analyses of pathogen groups, mixed 476 
infections, and pathogen count. * P <0.05. Abbreviations: Bac, bacteria; EAEC, enteroaggregative 477 
Escherichia coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; EV, enterovirus; Euk, 478 
eukaryote; OR, odds ratio; Vir, virus; w, weeks. 479 
 480 
Figure 2. Association between concurrent pathogens and Rotarix replication. (A) Prevalence of 481 
concurrent pathogens at 6 weeks of age according to shedding status at 4 and/or 7 days after the first dose 482 
of RV1. Pathogens present in at least 1% of the study population are included. (B, C) Prevalence of Sabin 483 
viruses and NPEVs at 6 and 10 weeks of age according to shedding status. (D) Prevalence of 484 
enteroviruses at 10 weeks of age according to the shedding of ≥1 Sabin virus at 6 weeks The shedding of 485 
Sabin viruses at 10 weeks of age was used as an indicator of take following the OPV dose administered at 486 
6 weeks. * P <0.05; ** P <0.005. Abbreviations: Bac, bacteria; EAEC, enteroaggregative Escherichia 487 
coli; EPEC, enteropathogenic E. coli; ETEC, enterotoxigenic E. coli; Euk, eukaryote; EV, enterovirus; 488 
RV, rotavirus; Sabin+, positive for ≥1 Sabin serotype; Sabin-, negative for all Sabin serotypes; STEC, 489 
Shiga toxin-producing E. coli; Vir, virus; w, weeks. 490 
 491 
Figure 3. Association between microbiota diversity and Rotarix response. (A) Phylum- and genus-492 
level composition of the bacterial microbiota at 6 and 10 weeks of age. (B) OTU count and Shannon 493 
index (mean ± standard error) by rotavirus seroconversion status. (C) Unweighted Unifrac distances 494 
between 6-week samples, visualized via principal coordinates analysis. (D, E) Equivalent plots are 495 
displayed with respect to shedding status after the 6-week RV1 dose. * P <0.05. Abbreviations: OTU, 496 
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97%-identity operational taxonomic unit; PC, principal coordinate; RV, rotavirus; RV1, Rotarix; w, 497 
weeks. 498 
 499 
Figure 4. Impact of probiotic supplements on the bacterial microbiota. (A) Receipt of probiotics 500 
resulted in enrichment of a single OTU (classified as L. zeae). Mean relative abundance of this OTU in 501 
each study arm is indicated by a horizontal line, while prevalence is indicated by a cross. (B) OTU count 502 
and Shannon index (mean ± standard error) by study arm. (C) Unweighted Unifrac distances between 6-503 
week samples, visualized via principal coordinates analysis. (D) Mean accuracy (± SD) across 100 504 
iterations of the Random Forest algorithm for models predicting receipt of probiotics-only (upper) or zinc 505 
and probiotics (lower). OTU 21300 corresponds to the Lactobacillus strain that was enriched among 506 
probiotics recipients. (E, F) Highest-ranking taxa by Random Forest importance score (mean decrease in 507 
accuracy ± SD) for models predicting receipt of (E) probiotics-only and (F) zinc and probiotics. * P 508 
<0.05; ** P <0.005. Abbreviations: LGG, probiotics (Lactobacillus rhamnosus GG); OTU, 97%-identity 509 
operational taxonomic unit; PC, principal coordinate; w, weeks; Zn, zinc. 510 
Table 1. Baseline characteristics.
Enteropathogen subset Microbiota subset
Responders 
(n = 162)
Non-
responders 
(n = 163)
      
p
Responders 
(n = 85)
Non-
responders 
(n = 85)
      
p
Completed the study per protocol 159 (98.1) 161 (98.8) 1.000 85 (100) 84 (98.8) 1.000
Treatment group
     Placebo 36 (22.2) 37 (22.7) - 32 (37.6) 31 (36.5) -
     Zinc 35 (21.6) 34 (20.9) 0 (0.0) 0 (0.0)
     Probiotics 39 (24.1) 39 (23.9) 34 (41.2) 35 (40.0)
     Zinc/probiotics 52 (32.1) 53 (32.5) 19 (22.4) 19 (22.4)
Age at enrollment (days) 35.8 (1.8) 35.9 (1.9) 0.577 36.0 (1.8) 36.0 (2.0) 0.933
Female 86 (53.1) 88 (54.0) 0.912 42 (49.4) 46 (54.1) 0.645
Mother’s education
     None 11 (6.8) 8 (4.9) 0.901 4 (4.7) 4 (4.7) 0.677
     Primary 24 (14.8) 29 (17.8) 10 (11.8) 13 (15.3)
     Secondary 86 (53.1) 87 (53.4) 50 (58.8) 42 (49.4)
     Higher secondary 25 (15.4) 25 (15.3) 12 (14.1) 18 (21.2)
     Degree/diploma 16 (9.9) 14 (8.6) 9 (10.6) 8 (9.4)
House type
     Kutcha (temporary materials) 10 (6.2) 9 (5.5) 0.255 7 (8.2) 3 (3.5) 0.240
     Mixed 55 (34) 70 (42.9) 28 (32.9) 36 (42.4)
     Pucca (permanent materials) 97 (59.9) 84 (51.5) 50 (58.8) 46 (54.1)
Health status
     Any breastfeeding at enrollment 162 (100) 162 (99.4) 1.000 85 (100) 85 (100) 1.000
     Positive for rotavirus IgA at baseline 42 (25.9) 45 (27.6) 0.802 18 (21.2) 26 (30.6) 0.220
     Diarrhea at 6 or 10 weeks 11 (6.8) 12 (7.4) 1.000 5 (5.9) 7 (8.2) 0.766
     Stunted at 6 or 10 weeks 37 (22.8) 51 (31.3) 0.105 22 (25.9) 25 (29.4) 0.732
     Underweight at 6 or 10 weeks 25 (15.4) 39 (23.9) 0.069 17 (20.0) 15 (17.6) 0.845
Data are mean (standard deviation) or n (%). Responders and non-responders were compared using Wilcoxon’s 
rank sum test or Fisher’s exact test. Stunting was defined as a height-for-age Z score of < -2 and underweight as 
a  weight-for-age Z score  of  <  -2.  One non-responder  in  the  microbiota  subset  was excluded from the final 
analyses owing to a clerical error that led to inclusion of the incorrect samples.
Figures
Figure 1
 
A
B
C    D                    E
Figure 2
B             C              D
A
Figure 3
A
B                            C       D                          E
Figure 4
30
40
50
60
6w 10w
Ac
cu
ra
cy
 (%
)
Seroconversion
30
40
50
60
70
6w 10w
Ac
cu
ra
cy
 (%
) **
Dose 1 take
45
55
65
75
85
6w 10w
Ac
cu
ra
cy
 (%
)
Full data Exc. OTU 21300
**
	
**
	
LGG
45
55
65
75
85
6w 10w
Full data Exc. OTU 21300
**
	 **
	*
	
*
	
ZincPro (full)    
40
50
60
70
80
90
6w 10w
Ac
cu
ra
cy
 (%
)
Full data Exc. OTU 21300
**
	
**
	 *
	
Zn/LGG
30
40
50
60
6w 10w
Ac
cu
ra
cy
 (%
)
Seroconversion
30
40
50
60
70
6w 10w
Ac
cu
ra
cy
 (%
) **
Dose 1 take
45
55
65
75
85
6w 10w
Ac
cu
ra
cy
 (%
)
Full data Exc. OTU 21300
**
	
**
	
LGG
45
55
65
75
85
6w 10w
Full data Exc. OTU 21300
**
	 **
	*
	
*
	
ZincPro (full)    
40
50
60
70
80
90
6w 10w
Ac
cu
ra
cy
 (%
)
Full data Exc. OTU 21300
**
	
**
	 *
	
Zn/LGG
A                                               B  C
D                                E F
  
Supplemental Appendix (clean)
Click here to download Supplemental Files: (3) Supplementary Appendix, revised, clean.docx
  
Supplemental Tables and Figures
Click here to download Supplemental Files: (4) Supplementary Tables and Figures, TAC-16S, 20-July-17.pdf
  
Metadata
Click here to download Supplemental Files: Parker_et_al_2017_ZPS_metadata.csv
  
OTU table (biom format)
Click here to download Supplemental Files: Parker_et_al_2017_ZPS_otu_table.biom
  
OTU table (csv format)
Click here to download Supplemental Files: Parker_et_al_2017_ZPS_otu_table.csv
